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Abstract
Mutations in epithelial growth factor receptor (EGFR), as well as in the EGFR downstream
target KRAS are frequently observed in non-small cell lung cancer (NSCLC). Chronic
obstructive pulmonary disease (COPD), an independent risk factor for developing NSCLC,
is associated with an increased activation of EGFR. In this study we determined presence
of EGFR and KRAS hotspot mutations in 325 consecutive NSCLC patients subjected to
EGFR and KRASmutation analysis in the diagnostic setting and for whom the pulmonary
function has been determined at time of NSCLC diagnosis. Information about age at diagno-
sis, sex, smoking status, forced vital capacity (FVC) and forced expiratory volume in 1 sec
(FEV1) was collected. Chronic obstructive pulmonary disease(COPD) was defined accord-
ing to 2013 GOLD criteria. Chi-Square, student t-test and multivariate logistic regression
were used to analyze the data. A total of 325 NSCLC patients were included, 193 with
COPD and 132 without COPD. COPD was not associated with presence of KRAS hotspot
mutations, while EGFRmutations were significantly higher in non-COPD NSCLC patients.
Both female gender (HR 2.61; 95% CI: 1.56–4.39; p<0.001) and smoking (HR 4.10; 95%
CI: 1.14–14.79; p = 0.03) were associated with KRASmutational status. In contrast, only
smoking (HR 0.11; 95% CI: 0.04–0.32; p<0.001) was inversely associated with EGFRmuta-
tional status. Smoking related G>T and G>C transversions were significantly more frequent
in females (86.2%) than in males (61.5%) (p = 0.008). The exon 19del mutation was more
frequent in non-smokers (90%) compared to current or past smokers (36.8%). In conclu-
sion, KRASmutations are more common in females and smokers, but are not associated
with COPD-status in NSCLC patients. EGFRmutations are more common in non-smoking
NSCLC patients.
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Introduction
Chronic obstructive pulmonary disease (COPD) is associated with lung cancer also after
accounting for other respiratory diseases and smoking [1–2]. An increased risk of lung cancer
in COPD patients was evident in a meta-analysis [2]. About one third of smokers with COPD
died of lung cancer within a follow-up of 14.5 years [3]. On the other hand, 50–70% of the lung
cancer patients have COPD according to results of pulmonary function tests at time of diagno-
sis [4]. In a more recent, large prospective study, the association between COPD and lung can-
cer was largely explained by smoking [5]. The odds ratio (OR) for patients diagnosed with
COPD to develop lung cancer within a period of 6 months was 11.4. However, the OR dropped
to 6.8 after correction for smoking [5]. This is consistent with the notion that COPD has been
recognized as an independent risk factor for developing lung cancer [6].
KRAS is involved in regulation of cell proliferation [7]. Mutations in KRAS are mostly
found in codons 12, 13 and 61 and result in constitutive activation of the protein [8]. KRAS
mutations are observed more frequent in smoking patients with adenocarcinoma (5–40%)
than in the other subtypes of lung cancer [7, 9]. Mutations in KRAS are associated with poorer
prognosis of NSCLC patients [10]. Moreover, a COPD-like airway inflammation can increase
lung carcinogenesis in the presence of the p.G12D K-ras activating mutation in a mouse model
[11].
EGFR plays a crucial role in wound healing and tissue repair in the lung, especially in the
bronchial wall. Overexpression of EGFR was reported in the bronchial mucosa of non-smoking
asthmatic individuals compared to normal controls [12]. Moreover, prolonged activation of
EGFR leads to metaplasia [13]. Exposure of epithelial cells to cigarette smoke induced aberrant
phosphorylation and activation of EGFR and this may subsequently mediate development of
lung cancer [14–15]. Mutations in the kinase domain also lead to activation of the EGFR path-
way independent of binding to its ligand [16]. These activating EGFRmutations are common
in non-small cell lung cancer (NSCLC) with a frequency of about 10–15% in Caucasians [17–
18]. EGFRmutations have been associated with non-smoking NSCLC patients [19]. The p.
(L858R) in exon 21 (referred to as L858R) and deletions in exon 19 (referred to as exon 19del)
of the EGFR gene are the most commonly observed activating mutations [20]. We previously
showed a significant association between EGFRmutations and clinical outcome [21]. In vivo
studies in mouse models conditionally expressing either the L858R or an exon19del mutant
allele of the human EGFR gene have supported the role of these mutations in initiation and
development of lung cancer [22].
Smoking is a known risk factor for both COPD and lung cancer [23–24]. KRASmutations
are described as a signature for cigarette smoking [25], while EGFRmutations are more com-
mon in non-smokers. We hypothesize that KRASmutations are positively associated with
COPD status in NSCLC patients, while activating EGFRmutations are negatively associated
with COPD in NSCLC patients. To study this hypothesis we analyzed NSCLC patients
screened for the presence of EGFR and KRASmutations in a diagnostic setting and investigated
whether the presence of EGFR and KRASmutations in NSCLC patients was related to COPD.
Materials and Methods
Patients
Consecutive patients with advanced NSCLC, diagnosed between November 2008 and July
2012, and for whom KRAS and EGFRmutation analysis was performed in a clinical setting,
were selected for this study. In this cohort we further selected patients for whom lung function
data were available. All patients had stage IV NSCLC and had one or more visceral metastases
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at diagnosis. Previously, 165 of the NSCLC patients have been described in a study on EGFR
and KRASmutations in relation to clinical outcome [21]. Patients with NSCLC post lung trans-
plantation were excluded from this study. For all patients, data on gender, smoking status
(including pack year if available), age at diagnosis, stage at diagnosis according to the 6th TNM
edition, localization of metastases, start date and (different) lines of treatment were collected.
Data on lung function was newly collected for all patients included in this study. All procedures
and protocols were performed according to the guidelines for good clinical practice and after
informed consent was obtained from all patients.
Informed Consent and Ethics
Written informed consent for blood and tumor tissue from all patients was obtained before
biobanking. This procedure was approved by the Medical Ethical Committee of the University
Medical Center Groningen. This study was conducted in accordance with the provisions of the
Declaration of Helsinki and Good Clinical Practice guidelines. For this study, all patient data
were anonymized and de-identified prior to analysis. Besides the mutational analysis, pulmo-
nary function tests were performed as part of routine diagnostic approach and the outcome of
these tests was documented in the patient file and communicated with patients. Due to the ret-
rospective nature of this study, under Dutch Law for human medical research (WMO), no spe-
cific permission was compulsory from the Institutional Review Board.
Pulmonary function testing
Spirometry was performed with a daily-calibrated pneumotachograph (MasterscreenPneumo,
Jaeger, Wurzburg, Germany) according to standardized guidelines [26]. Lung function tests are
provided after bronchodilatator (salbutamol 100 microgram). Patients were defined as having
COPD if the forced expiratory volume in 1 sec (FEV1)/forced vital capacity (FVC) (FEV1/
FVC) was<0.70 with fixed bronchial obstruction over time not due to endobronchial tumor
obstruction. Staging of COPD was performed according to GOLD criteria [27].
Histology and KRAS/EGFRmolecular testing
Tumor samples were obtained either by bronchoscopy, transthoracic lung biopsies and/or
from pulmonary resections. Histological subtyping was performed according to 2004 WHO
criteria [28]. Mutational analysis was performed as previously described [21].
Statistics
For normally distributed data we show mean and standard deviation (SD) and used a student
t-test to determine significant differences. For not normally distributed data median and range
are given and Chi-Square test is used to determine significance. Logistic regression was per-
formed to study whether the presence of COPD had any effect on KRAS or EGFRmutational
status using sex, age, histology, and smoking as covariates. Statistical analysis was performed
using SPSS version 22.0. Nominal P-values less than 0.05 were considered significant. Data are
available in S1 Table.
Results
Patient characteristics and KRAS/EGFRmutations
A total of 325 stage IV NSCLC patients were included. Over 80% had adenocarcinoma, 174
(53.5%) were male and 151 (46.5%) female. The mean age at time of diagnosis was 63.6 (±10.5
years). One hundred and five patients (32.3%) had a KRASmutation. For 1 out of 105 patients
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with a KRASmutation, the type of mutation was inconclusive with a positive high resolution
melting (HRM) PCR result, but with a wild type sequence based on the Sanger sequencing
result. For one patient with an EGFRmutation, the KRASmutation status was not available.
The remaining 219 patients did not have mutations in the KRAS hotspot region. Twenty-nine
patients (8.9%) had an EGFRmutation. In five patients, the EGFRmutational status was not
available; four of these patients did have a KRASmutation. The other 291 patients did not have
EGFRmutations in the hotspot regions. The mean age of the males was higher than the mean
age of the females (66.3 ±9.8 years vs. 60.5 ±10.5 years; p<0.001). Males showed a significant
higher number of smoking pack years than females (mean 37.5 ±20.6 pack years vs. 30.1 ±15.7
pack years; p = 0.015).
Patient characteristics in COPD stratified subgroups
Almost 60% (193/325) of the NSCLC patients had COPD. Two third of the COPD cases were
males. The distribution of females was almost equal in COPD and non-COPD groups
(Table 1). Mean age in the COPD group was higher with 65.6 years (±9.9 years) compared to
the non-COPD group with 60.6 (±10.8 years) (p<0.001). We found a significant relationship
between smoking and COPD, 62.6% of current or past smokers had COPD, while only 18.2%
of non-smokers had COPD (p<0.001). A logistic regression model for COPD using sex, age
and smoking as covariates revealed significant associations with age (Hazard ratio [HR] 1.05;
95% confidence interval [CI]: 1.02–1.07; p<0.001) and smoking (HR 8.28; 95% CI: 2.61–26.24;
p<0.001), but not with gender (Table 2).
Table 1. NSCLC patient characteristics according to COPD status.
Characteristics COPD (%) N = 193 Non-COPD (%) N = 132 p-value
Sex
Female 77 (51) 74 (49) 0.004†
Male 116 (66.7) 58 (33.3)
Age at diagnosis, Mean (±SD) 65.6 (±9.9) 60.6 (±10.8) <0.001*
Histology
Adenocarcinoma 154 (59) 107 (41) 0.777†
Adeno-squamous 14 (66.7) 7 (33.3)
NSCLC-NOS 25 (58.1) 18 (41.9)
Smoking status#
Current or past smoker 184 (62.6) 110 (37.4) <0.001†
Non-smoker 4 (18.2) 18 (81.8)
FEV1%, Mean (±SD) 72.8 (±18.7) 90.2 (±19.4) -
FEV1/FVC ratio, Mean (±SD) 0.58 (±0.09) 0.76 (±0.05) -
KRAS mutation#
Yes 66 (62.9) 39 (37.1) 0.404†
No 127 (58) 92 (42)
EGFR activating mutation#
Yes 9 (31) 20 (69) 0.001†
No 180 (61.9%) 111 (38.1)
* T-test;
†Chi-square test;
#Missing data for smoking (n = 9), KRAS (n = 1) and EGFR (n = 5) status.
doi:10.1371/journal.pone.0152317.t001
COPD Is Not Associated with KRASMutations in NSCLC
PLOSONE | DOI:10.1371/journal.pone.0152317 March 23, 2016 4 / 11
COPD and tumor KRAS/EGFR hotspot mutations
KRASmutations were observed more often in females compared to males (65/151 (43%) versus
40/173, (23%); p<0.001) and also more often in current or past smokers (34.5%) than in non-
smokers (13.6%) (p = 0.045) (Table 3). KRASmutations were not significantly different
between COPD (34.2%) and non-COPD patients (29.8%) (Table 1), sothe presence of KRAS
mutations were independent of COPD. Stratification according to FEV1/FVC and GOLD stage
did not reveal a significant association with presence of KRASmutation (Fig 1A and 1B). How-
ever, FEV1 percentage as a continuous variable was significantly related to the presence of
KRASmutations (Fig 1C), but not in a multivariate analysis. Putting the variables (sex, age,
smoking and COPD) in a logistic regression model confirmed the significant association
Table 2. Logistic regression analysis of patient characteristics associated with COPD,KRAS and EGFR.
Characteristics COPD KRAS EGFR
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Sex 0.78 0.48–1.29 0.33 2.61 1.56–4.39 <0.001 1.21 0.51–2.90 0.66
Age 1.05 1.02–1.07 <0.001 0.99 0.97–1.01 0.39 0.98 0.95–1.02 0.39
Smoking 8.28 2.61–26.24 <0.001 4.10 1.14–14.79 0.03 0.11 0.04–0.32 <0.001
COPD - - - 1.29 0.77–2.18 0.34 0.44 0.18–1.09 0.08
HR: Hazard ratio; CI: Conﬁdence interval
doi:10.1371/journal.pone.0152317.t002
Table 3. NSCLC patient characteristics andKRAS/EGFRmutation*.
Characteristics KRAS mutation Pearson Chi-Square EGFR mutation Pearson Chi-Square
No (%) Yes (%) No (%) Yes (%)
Sex
Female 86 (57) 65 (43) <0.001 130 (87.8) 18 (12.2) 0.07
Male 133 (76.9) 40 (23.1) 161 (93.6) 11 (6.4)
Smoking status
Current or past smoker 192 (65.5) 101 (34.5) 0.045 270 (93.4) 19 (6.6) <0.001
Nonsmoker 19 (86.4) 3 (13.6) 12 (54.5) 10 (45.5)
* Missing data for smoking (n = 9), KRAS (n = 1) and EGFR (n = 5) status.
doi:10.1371/journal.pone.0152317.t003
Fig 1. KRASmutations and severity of airflow obstruction. (A) FEV1/FVC, (B) COPDGOLD classification and (C) FEV1 percentage in KRASmutant and
wildtype patients with NSCLC. aP-value was calculated by student t-test. bP-value was calculated by Chi-square test.
doi:10.1371/journal.pone.0152317.g001
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between KRAS hotspot mutations with female sex (HR 2.61; 95% CI: 1.56–4.39; p<0.001) and
smoking (HR 4.10; 95% CI: 1.14–14.79; p = 0.03) (Table 2).
EGFRmutations showed a trend to a higher frequency in females compared to males,
(p = 0.073). Ten out of 22 (45.5%) non-smokers had activating EGFRmutations, while only 19
out of 289 (6.5%) of the current or past smokers had an EGFRmutation (p<0.001). EGFR
mutations were observed more often in the non-COPD (20/131, i.e. 15.3%) as compared to the
COPD group (9/189, i.e. 4.8%)(p = 0.001) (Table 3). Using sex, age, smoking and COPD as
covariates in a logistic regression model for EGFRmutations, confirmedsignificant inverse
association between smoking (HR 0.11; 95% CI: 0.04–0.32; p<0.001) and EGFRmutational
status (Table 2).
COPD and type of KRAS/EGFRmutations
The KRAS p.(G12C) was the most common amino acid change in both male and female with a
frequency of approximately 41%. The p.(G12V) and p.(G12D) mutations were the second
most frequent mutations in females and males, with a frequency of 20% and 25.6%, respectively
(Table 4). Forty-three percent of the KRASmutations in the current or past smoker group were
p.(G12C) mutations, while none of the non-smoking patients had this mutation. In addition,
G>T and G>C transversions in KRAS occurred in 86.2% of the females and in 61.5% of the
males. The G>A transition was more common in males than in females (p = 0.008)(Table 5).
COPD status was not associated with any type of KRAS amino acid changes or nucleotide
substitutions.
Of all EGFRmutation positive cases the percentage of patients with an exon 19del was not
significantly different between females (11/18) and males (5/11). In non-smokers, 9 out of 10
EGFRmutation positive cases had an exon 19del (Table 6), whereas in current or past smokers
only 7 out of 19 patients with an EGFRmutation had an exon 19del.
Discussion
In contrast to our hypothesis we showed that COPD is not associated with the presence of
KRASmutations in lung cancer, whereas presence of EGFRmutations was more frequent in
Table 4. Distribution of different KRAS amino acid changes in advanced NSCLC patients*.
Characteristics KRAS amino acid change Pearson Chi-Square
p.(G12C) (%) p.(G12V) (%) p.(G12A) (%) p.(G12D) (%) Other (%)
Sex
Female 27 (41.5) 13 (20) 7 (10.8) 6 (9.2) 12 (18.8) 0.20
Male 16 (41) 5 (12.8) 2 (5.1) 10 (25.6) 6 (15.4)
Histology
Adenocarcinoma 41 (42.7) 16 (16.7) 8 (8.3) 13 (13.5) 18 (18.8) 0.26
NSCLC NOS 2 (25) 2 (25) 1(12.5) 3 (37.5) 0
Smoking status
Current or past smoker 43 (43) 17 (17) 7 (7) 15 (15) 18 (18) 0.24
Nonsmoker 0 1 (33.3) 1 (33.3) 1 (33.3) 0
COPD
Yes 27 (40.9) 11 (16.7) 6 (9.1) 11 (16.7) 11 (16.7) 0.99
No 16 (42.1) 7 (18.4) 3 (7.9) 5 (13.2) 7 (18.4)
* Missing data for smoking (n = 1) status and type of KRAS mutation (n = 1); p.(G12C) and p.(G12V) (G>T), p.(G12A) (G>C), p.(G12D) (G>A).
doi:10.1371/journal.pone.0152317.t004
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non-COPD as compared to COPD lung cancer patients, after correcting for sex and smoking.
We found significantly higher mean age in the COPD group as compared to the non-COPD
group. This finding is consistent with the fact that the COPD prevalence increases with age
[29].
KRASmutations were identified in 32% of the NSCLC patients, which mainly included
adenocarcinoma patients. We observed a relationship between presence of KRAS hotspot
mutations and smoking status consistent with previous studies [25, 30], but not with
Table 5. Distribution of different KRAS nucleotide changes in advanced NSCLC patients*.
Characteristics KRAS mutations Pearson Chi-Square*
Transversions G>T, G>C (%) Transitions G>A (%) Other (%)
Sex
Female 56 (86.2) 7 (10.8) 2 (3.1) 0.008
Male 24 (61.5) 14 (35.9) 1 (2.6)
Histology
Adenocarcinoma 75 (78.1) 18 (18.8) 3 (3.1) 0.41
NSCLC NOS 5 (62.5) 3 (37.5) 0
Smoking
Current or past smoker 77 (77) 20 (20) 3 (3) 0.83
Nonsmoker 2 (66.7) 1 (33.3) 0
COPD
Yes 50 (75.8) 14 (21.2) 2 (3) 0.93
No 30 (78.9) 7 (18.4) 1 (2.6)
* Missing data for smoking (n = 1) status and type of KRAS mutation (n = 1).
doi:10.1371/journal.pone.0152317.t005
Table 6. Distribution of different EGFRmutations in advanced NSCLC patients.
Characteristics EGFR mutations Pearson Chi-Square
Exon 19del (%)* p.(L858R) (%)† Other (%)‡
Sex
Female 11 (61.1) 4 (22.2) 3 (16.7) 0.69
Male 5 (45.5) 3 (27.3) 3 (27.3)
Histology
Adenocarcinoma 16 (57.1) 6 (21.4) 6 (21.4) 0.20
NSCLC NOS 0 1 (100) 0
Smoking
Current or past smoker 7 (36.8) 6 (31.6) 6 (31.6) 0.02
Nonsmoker 9 (90) 1 (10) 0
COPD
Yes 5 (55.6) 3 (33.3) 1 (11.1) 0.60
No 11 (55) 4 (20) 5 (25)
* One patient had an exon 19del and p.(T790M),
†One patient had a p.(L858R) and p.(T790M),
‡ One patient had a p.(G719S) and p.(S768I) and another patient had a p.(G719C) and an exon 20 insertion.
doi:10.1371/journal.pone.0152317.t006
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COPD. In other studies no relation between smoking and the presence of KRASmutations
have been observed in lung cancer patients[25, 30–32]. These differences may be caused by
differences in selecting study groups, ethnicity, number of patients and smoking status. The
lack of an association with COPD is in concordance with the results reported ina recent
study [33].
Although smoking females were younger and lighter smokers based on pack years than the
males, we noticed that KRASmutations were more common in smoking females than in
smoking males with NSCLC. This supports an increased susceptibility of females to cigarette
carcinogens as reported previously [34]. Moreover, these results are also consistent with a pre-
vious study showing that females had a higher OR for lung cancer at every level of tobacco
exposure [35]. This elevated vulnerability to smoking may be caused by the higher expression
levels of genes encoding tobacco carcinogen-metabolizing enzymes, such as CYP1A1 and
CYP1B1, in normal lung tissue of female smokers in comparison to male smokers [36].
Uppstad and colleagues [37] also showed higher expression of CYP1A1 in cell lines derived
from lung adenocarcinoma of female compared to cell lines derived from adenocarcinomas of
male patients.
Although we observed the smoking related p.(G12C) KRASmutation at the same frequency
in both genders, smoking related transversions, i.e. G>T and G>C, were significantly more
common in females than in males. In a previous study with a sample size of over 2,500 patients,
the c.34G>T; p.(G12C) KRASmutation occurred more frequent in females and current or past
smokers, while the c.35G>A; p.(G12D) KRASmutations were more frequent in never smokers
[20]. This suggests again that females are more susceptible of cigarette smoke related KRAS
mutations compared to males.
We showed that EGFR activating mutations were more common in females, non-smokers
and in non-COPD NSCLC patients. In a recent study, EGFRmutations were seen in 12.8%
(51/399) of lung cancer patients without COPD and in 6.3% (7/111) of patients with COPD
[38]. Suzukiand colleagues [39]identified EGFRmutations in 32% (56/177) of the non-COPD
and in 8% (4/52) of the COPD NSCLC patients. Lim and colleagues[33] found EGFRmuta-
tions in 37.3% (91/244) of non-COPD and in 16% (17/106) of COPD patients. They also found
an inverse association between the presence of EGFRmutation with severity of airflow obstruc-
tion. The finding that EGFRmutations are more common in non-COPD lung cancer patients
might indicate that lung cancer development is dependent on activating EGFRmutations in
non-COPD patients.Chronic pulmonary diseases, such as severe asthma and COPD, cause an
increased activation of the epithelial growth factor receptor (EGFR)[12, 40]. Moreover, COPD
is characterized by epithelial inflammatory reactions and many pro-inflammatory chemokines
and growth factors are induced by transcription factor Nuclear Factor kB (NFkB). This tran-
scription factor can be activated via physical and chemical stress such as smoke [41]. In addi-
tion, increased activation of EGFR by oxidative stress, which is involved in pathogenesis of
COPD, or cigarette smoke can occur in human bronchial epithelial cells [14–15, 42]. All
together suggesting that EGFR activation in COPD is induced by smoking, oxidative stress and
subsequently by inflammation probably via NFkB.
In conclusion, KRASmutations were more common in females and smokers, but are not
associated with COPD-status in NSCLC patients. EGFRmutations are more common in
females and non-smoking NSCLC patients.
Supporting Information
S1 Table. Patients data used for statistical analysis.
(XLSX)
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